A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

NCT ID: NCT01981850

Last Updated: 2022-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 125 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-10-01
• Study Completion Date: 2020-07-10

Brief Summary

RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue.

The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.

Detailed Description

Stage 1 of this study has completed. Stage 1 was an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety of two different dose schedules of RO7490677 in participants with PMF and post ET/PV MF. There were two treatment cohorts, each assigned to one of two dose schedules receiving either single-agent RO7490677 or RO7490677 in combination with ruxolitinib. Participants were assigned to a weekly or every four week dosing schedule by the investigator.

Stage 2 is a randomized, double-blind Phase 2 study to determine the efficacy and safety of three different doses of RO7490677 in participants with PMF and post ET/PV MF. Participants will be randomized to one of three doses: 0.3 mg/kg, 3.0 mg/kg or 10 mg/kg of RO7490677. This is the second stage of an adaptive design study as defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, February 2010. Modifications to dose levels, schedule, and regimen have been made in Stage 2 based on data from Stage 1.

Conditions

Primary Myelofibrosis; Polycythemia Vera; Post-Essential Thrombocythemia Myelofibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Stage 1: Cohort 1 Weekly

Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Stage 1: Cohort 1 Every 4 Weeks

Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Stage 1: Cohort 2 Weekly

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Ruxolitinib

Intervention Type: DRUG

IV infusion

Stage 1: Cohort 2 Every 4 Weeks

Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Ruxolitinib

Intervention Type: DRUG

IV infusion

Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks

Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Stage 2: Cohort 2 3mg/kg Every 4 Weeks

Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Stage 2: Cohort 3 10mg /kg Every 4 Weeks

Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

Group Type: EXPERIMENTAL

RO7490677

Intervention Type: BIOLOGICAL

IV infusion

Interventions

RO7490677

IV infusion

Intervention Type: BIOLOGICAL

Ruxolitinib

IV infusion

Intervention Type: DRUG

Other Intervention Names

originally called PRM-151, and also known as rhPTX-2; Jakafi

Eligibility Criteria

Inclusion Criteria

1. Participants must be ≥18 years of age at the time of signing the Informed Consent Form (ICF);

2. Participants must voluntarily sign an ICF;

3. Participants must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;

4. At least Grade 2 marrow fibrosis according to the WHO Grading of Bone Marrow Fibrosis;

5. Intermediate-1, intermediate -2, or high risk disease according to the IWG -MRT Dynamic International Prognostic Scoring System

6. A bone marrow biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;

7. Participants must not be candidates for ruxolitinib based on EITHER:

1. Platelet count < 50 x 10e9/L, OR

2. Hgb < 100 g/L, have received ≥ 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;

8. Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. (Appendix F);

9. Life expectancy of at least twelve months;

10. At least four weeks must have elapsed between the last dose of any MF- directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;

11. Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;

12. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤55 years or 12 months if >55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception are outlined in the protocol.

13. Ability to adhere to the study visit schedule and all protocol requirements;

14. Must have adequate organ function as demonstrated by the following:

• ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
• Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
• Serum creatinine ≤ 2.5 mg/dL x ULN.

Exclusion Criteria

1. White blood cell count > 25 x 10e9/L or > 10% peripheral blood blasts;

2. Other invasive malignancies within the last 3 years, except non- melanoma skin cancer and localized cured prostate and cervical cancer;

3. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;

4. Presence of active serious infection;

5. Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the participant from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;

6. Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection;

7. Organ transplant recipients other than bone marrow transplant;

8. Women who are pregnant or lactating.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Mayo Clinic Cancer Center

Phoenix, Arizona, United States

Stanford Cancer Institute

Palo Alto, California, United States

Emory Hospital

Atlanta, Georgia, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Mount Sinai Medical Center

New York, New York, United States

Weill Cornell Medical Center

New York, New York, United States

Wake Forest Baptist Medical Center

Winston-Salem, North Carolina, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

Providence Health Care

Vancouver, British Columbia, Canada

The Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Hospital Saint-Louis

Paris, , France

University Medical Center RWTH Aachen

Aachen, , Germany

Johannes Wesling Academic Medical Center

Minden, , Germany

Hadassah Medical Centre

Jerusalem, , Israel

Meir Medical Centre

Kfar Saba, , Israel

Fondazione IRCCS Policlinico San Matteo

Pavia, , Italy

Marche Nord Hospital

Pesaro, , Italy

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

Radboud University Medical Center

Nijmegen, , Netherlands

Guy's and St. Thomas' Hospital

London, , United Kingdom

Countries

United States; Canada; France; Germany; Israel; Italy; Netherlands; United Kingdom

References

Verstovsek S, Foltz L, Gupta V, Hasserjian R, Manshouri T, Mascarenhas J, Mesa R, Pozdnyakova O, Ritchie E, Veletic I, Gamel K, Hamidi H, Han L, Higgins B, Trunzer K, Uguen M, Wang D, El-Galaly TC, Todorov B, Gotlib J. Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023 Oct 1;108(10):2730-2742. doi: 10.3324/haematol.2022.282411.

Reference Type: DERIVED

PMID: 37165840 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

PRM-151G-101

Identifier Type: OTHER

Identifier Source: secondary_id

2015-001718-80

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

BO42355

Identifier Type: -

Identifier Source: org_study_id